Michael Thomas Henderson

CEO Michael Thomas Henderson sold 80,000 shares ($10.6M) at $132.54 under 10b5-1 plan; holds 1.02M post-sale in unprofitable $9.9B company.

Michael Thomas Henderson, as CEO, sold 80,000 shares (80.0K shares) for a total value of $10,603,200.00 ($10.6M) at $132.54 on 2026-06-22 under a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, reducing his holdings from 1,095,987 shares (1.10M shares) to 1,015,987 shares (1.02M shares). The sale occurs while the stock trades near its 52-week high of $133.16 (within 0.4% of peak) and after a strong 30-day surge of +63.5%, though this is a scheduled execution rather than a discretionary trade decision. Apogee Therapeutics reported a net loss of $74,111,000.00 ($-74.1M) in its most recent full fiscal year, indicating the company is unprofitable despite its market capitalization of $9,936,145,125.24 ($9.9B). The CEO's cross-ticker track record shows an average 90-day return of +22.6% after prior sells (20 prior sells across all tickers), though same-ticker measurable outcomes are not yet available for the five prior trades at APGE on 2026-06-10, making direct comparison of his historical timing accuracy at this specific ticker unavailable.

Director Michael Thomas Henderson sold 20,000 shares of SYRE at $100.00 on 2026-06-22 under pre-arranged 10b5-1 plan; stock now at $97.05

Michael Thomas Henderson (Director) executed a scheduled sale of 20,000 shares (20.0K shares) at $100.00 on 2026-06-22 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-06, reducing his holdings by -22.6% vs pre-transaction levels to 68.6K shares. The transaction occurred while the stock trades at $97.05, which is -4.9% from the 52-week high of $102.06 and reflects strong recent momentum (+31.1% over 30 days, +112.5% over 90 days). Spyre Therapeutics remains unprofitable with latest quarter revenue of $0.00 and full-year net income of $-69.0M, yet carries a market cap of $8.4B. Because this sale is scheduled under a 10b5-1 plan, it reflects predetermined timing rather than a discretionary decision, limiting its informational content as a directional signal about Henderson's current conviction in the stock.

CEO Michael Thomas Henderson sold 20,000 shares of APGE for $1.7M via 6 separate transactions on 2026-06-10 under pre-arranged 10b5-1 plan.

Michael Thomas Henderson, CEO of Apogee Therapeutics, executed six separate sales totaling 20,000 shares for $1,667,621.66 on 2026-06-10, reducing his holdings by 1.8% to 1,095,987 shares. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, meaning the sales were scheduled rather than discretionary. At current price of $88.33, the stock has risen 5.2% over the prior 30 days and 22.8% over 90 days, outpacing the blended transaction average of $83.38. The company reported a negative net income of $-74,111,000.00 for its most recent full fiscal year, indicating ongoing unprofitability despite recent stock price strength. The CEO's prior trades at APGE show mixed 30-day outcomes, though the scheduled nature of this plan removes timing from the analysis equation.

CEO Henderson sells 20,000 shares ($1.6M) via pre-arranged 10b5-1 plan at APGE; stock down 9.2% in 30 days.

Michael Thomas Henderson, CEO of Apogee Therapeutics, executed 2 separate sales totaling 20,000 shares for $1,641,710.73 on 2026-05-13 at an average price of $82.09 per share. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-08-13, meaning it was scheduled in advance rather than a discretionary decision. The sale reduced his holdings from 1.14M to 1.12M shares—a modest reduction relative to his total position. The company is unprofitable with net income of $-74,111,000.00, and the stock is currently trading at $81.14, down 9.2% over the past 30 days and down 14.9% from its 52-week high of $95.32. Since this trade is scheduled under a 10b5-1 plan, it does not reflect a timing decision by the CEO; rather, it represents a pre-planned reduction in holdings that occurred while the company operates at a loss and equity is under recent downward pressure.

Director Michael Thomas Henderson sells 80,000 shares for ~$5.95M as stock rallies sharply from 52-week lows.

Michael Thomas Henderson, a director at Spyre Therapeutics, disposed of a substantial portion of his holdings—80,000 shares totaling nearly $6M—in four tranches on the same day. This marks a significant shift in his insider activity: his prior Form 4 filings show 20 consecutive sales and no open-market purchases over the look-back period. The timing is notable given the stock's dramatic price trajectory—it has surged over 40% in the past month alone and more than doubled over three months from deeply depressed levels near its 52-week low. However, Henderson's selling pattern carries mixed track record implications: while his prior sales have shown a 35% win rate of being well-timed (where a 90-day decline would validate the sale), his overall 90-day returns after selling have been modestly positive, suggesting the stock often continued rising after his exits. Spyre remains unprofitable with no revenue, positioning any insider activity in a pre-commercial biotech context where cash management and equity decisions carry operational weight.

CEO Henderson sells 20,000 APGE shares for $1,651,664 while stock at 52-week high; 5 prior sells in 2 months

CEO Michael Thomas Henderson sold 20,000 shares across 3 separate transactions on 2026-04-08 for a blended average price of $82.58, generating $1,651,664.00 in proceeds. This reduces his holdings from 1,152,987 to 1,132,987 shares (-1.7%). The sale occurs with the stock trading at $86.27, only -0.3% from its 52-week high of $86.52. More notably, this represents the CEO's sixth discretionary sale at APGE in just two months: he executed five prior sales on 2026-03-11 and 2026-02-11, all of which have posted strong positive 30-day returns (ranging from +10.6% to +16.1%). The company is unprofitable, posting net income of $-65,021,000.00 for its most recent full fiscal year. The clustering of six sales by the CEO in a compressed timeframe, combined with the stock's proximity to its 52-week high and the company's negative profitability, warrants investor attention to assess whether the CEO's series of liquidations reflects confidence in current valuations or changing views on near-term prospects.

CEO Henderson sold 20,000 shares (20.0K shares) for $1,495,604.52 across 3 transactions at $74.78 avg

Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, executed 3 separate sales totaling 20,000 shares for $1,495,604.52 on March 11, 2026, at a blended average price of $74.78. The company is unprofitable with a net loss of $-65,021,000.00 for its most recent full fiscal year, and the stock is currently trading at $71.90, down 12.8% from its 52-week high of $82.43. Henderson's prior sell activity at APGE has shown mixed outcomes: three recent February sales generated 30-day returns of +14.2%, +10.6%, and +12.8%, while two January sales produced -17.8% and -16.3% 30-day returns. The sale reduces his holdings by 1.7% from 1,172,987 to 1,152,987 shares, maintaining substantial position ownership while the company operates at a significant loss.

CEO Michael Thomas Henderson sells 20,000 shares at blended avg $63.35; stock now $67.78, post-sale holding 1,172,987 shares

Michael Thomas Henderson, CEO of Apogee Therapeutics, executed 3 separate sales totaling 20,000 shares for $1,266,952.92 on 2026-02-11 at prices ranging from $62.96 to $64.99. The sales reduce his post-transaction holdings to 1,172,987 shares, a -1.7% reduction from his prior position. Henderson's cross-ticker track record shows 20 prior sells with an average 90-day return of -18.1% and a 60.00% well-timed rate, indicating he has historically sold before declines across his broader portfolio. However, at APGE specifically, his 5 prior trades (all sales on 2026-01-14) are still within their 30-day windows with negative returns ranging from -13.8% to -19.1%, and the company itself is unprofitable with a -$65,021,000 net income over its most recent fiscal year. The pattern of consecutive sell activity by the CEO at a loss-making company warrants attention, though the sales represent only 1.7% of his holdings.

CEO Henderson sells 20,000 shares at $78.64–$83.79 for $1.6M; holds 1.19M post-sale; stock +46.5% in 90 days, -65.0M net income

Michael Thomas Henderson (Chief Executive Officer) executed 6 separate sales totaling 20,000 shares for $1,622,159.12 on 2026-01-14 at prices ranging from $78.64 to $83.79, with a blended average of $81.11. The sale reduces his holdings by 1.6% to 1,192,987 shares but he maintains substantial ownership. Context shows tension: the stock has rallied 46.5% over the past 90 days and traded within 2.0% of its 52-week high of $82.43 at the time of the sales, yet the company reported net income of -$65,021,000 for its most recent full fiscal year. Henderson's cross-ticker track record across 20 prior sells shows a 90-day well-timed rate of 91.67%, but at APGE specifically, prior 90-day outcomes are not yet measurable. The timing of a sale near 52-week highs during a strong rally in an unprofitable company warrants investor attention to whether this reflects management's assessment of valuation relative to fundamentals.

CEO Henderson sold 20,000 shares (1.6% of holdings) for $1,507,656.55 on 2025-12-10 at blended average $75.38.

Michael Thomas Henderson, Chief Executive Officer of Apogee Therapeutics, executed 3 separate sales totaling 20,000 shares for $1,507,656.55 on 2025-12-10, reducing his holdings from 1.23M to 1.21M shares. The sales occurred at prices ($74.88, $75.79, $76.58) near the 52-week high of $77.08, during a period when the stock rose 22.2% over 30 days and 109.0% over 90 days. The company remains unprofitable with net income of $-65,021,000.00 over its most recent full fiscal year. His recent trading activity at APGE shows a pattern of repeated sales within the last month (2025-11-13, 2025-12-04, and 2025-12-10), which warrants attention to whether this reflects asset diversification or shifts in management's outlook on near-term value.